Friday - May 2, 2025

LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

Singular Genomics Systems Announces Updated Presentation Time at the Inaugural Gilmartin Group Emerging Growth Company Showcase

August 25, 2022 | Last Trade: US$20.01 0.00 0.00

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its presentation time at the Inaugural Gilmartin Group Emerging Growth Company Showcase has been updated.

The new time for the presentation is 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day as previously scheduled, Wednesday, August 31, 2022. Investors and other interested parties are invited to register and access a live webcast of the presentation by following this link. Following the event, an archived webcast of the presentation will be available at investor.singulargenomics.com under Presentations & Events.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine.

Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com


Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page